Physical and mental fatigue in parkinsons disease: Epidemiology, pathophysiology and treatment

Drugs and Aging

Volumn 26, Issue 3, 2009, Pages 195-208

  Lou, Jau Shin ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b CR120 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; METHYLPHENIDATE; MODAFINIL; NORADRENALIN;

ATTENTION; ATTENTION NETWORK TEST; COGNITION; COMORBIDITY; CORRELATION ANALYSIS; DRUG MECHANISM; DYSTHYMIA; EXERCISE TEST; FATIGUE; FATIGUE SEVERITY SCALE; FINGER TAPPING; FORCE GENERATION; GERIATRIC DEPRESSION SCALE; GOLD STANDARD; HUMAN; MOTIVATION; MOTOR PERFORMANCE; MULTIDIMENSIONAL FATIGUE INVENTORY; PARKINSON DISEASE; PARKINSON FATIGUE SCALE 16; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PHYSICAL FATIGUE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; REVIEW; SLEEP; TRANSCRANIAL MAGNETIC STIMULATION; VISUAL ANALOG SCALE;

ANTIPARKINSON AGENTS; FATIGUE; HUMANS; MENTAL FATIGUE; PARKINSON DISEASE; PSYCHOMETRICS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 64749098364     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200926030-00002     Document Type: Review

References (59)

1. Karlsen K, Larsen JP, Tandberg E, et al. Fatigue in patients with Parkinson's disease. Mov Disord 1999 Mar; 14: 237-41
2. Shulman LM, Taback R, Rabinstein AA, et al. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002 Jan 8; 193-7
3. Fauci AS, Braunwald E, Kasper DL, et al. Harrison's principles of internal medicine. 17th ed. New York: McGraw-Hill Medical, 2008
4. Lou JS, Kearns G, Oken B, et al. Exacerbated physical fatigue and mental fatigue in Parkinson's disease. Mov Disord 2001 Mar; 16: 190-6
5. Smets EMA, Grassen B, Bonke B, et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995 Apr; 39 (3): 315-25
6. Brown RG, Dittner A, Findley L, et al. The Parkinson Fatigue Scale. Parkinsonism Related Disord 2005; 11: 49-55
7. Krupp LB, LaRocca NG, Muir-Nash J, et al. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989 Oct; 46: 1121-3
8. Krupp LB, Avarez LA, Larocca NG, et al. Fatigue in multiple sclerosis. Arch Neurol 1988; 45: 435-7
9. Piper PF, Dibble SL, Dodd MJ, et al. The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum 1998; 25: 677-84
10. Piper PF, Lindsey AM, Dodd MJ, et al. The development of an instrument to measure the subjective dimension of fatigue. In: Funk SG, Tornquist EM, Champagne MT, et al., editors. Key aspects of comfort: management of pain, fatigue, and nausea. New York: Springer, 1989: 199-208
11. Dean GE, Spears L, Ferrell BR, et al. Fatigue in patients with cancer receiving interferon alpha. Cancer Pract 1995; 3: 164-72
12. Varvaro FF, Sereika SM, Zullo TG, et al. Fatigue in women with myocardial infarction. Health Care Women Int 1996; 17: 593-602
13. Grady C, Anderson R, Chase GA. Fatigue in HIV-infected men receiving investigational interleukin-2. Nurs Res 1998; 47: 227-34
14. Mendonca DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Mov Disord 2007 Oct; 22 (14): 2070-6
15. Havlikova E, van Dijk JP, Rosenberger J, et al. Fatigue in Parkinson's disease is not related to excessive sleepiness or quality of sleep. J Neurol Sci 2008; 270: 107-13
16. Oved D, Ziv I, Treves TA, et al. The effect of external rhythmic cues (auditory and visual) on walking during a functional task in homes of people with Parkinson's disease. Arch Phys Med Rehabil 2005 May; 86: 999-1006
17. Havlikova E, Rosenberger J, Nagyova I, et al. Impact of fatigue on quality of life in patients with Parkinson's disease. Eur J Neurol 2008; 15: 475-80
18. Rochester L, Hetherington V, Jones D, et al. Attending to the task: interference effects of functional tasks on walking in Parkinson's disease and the roles of cognition, depression, fatigue, and balance. Arch Phys Med Rehabil 2004; 85: 1578-85
19. Havlikova E, Rosenberger J, Nagyova I, et al. Clinical and psychosocial factors associated with fatigue in patients with Parkinson's disease. Parkinsonism Relat Disord 2008; 14: 187-92
20. Oved D, Ziv I, Treves TA, et al. Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease. Mov Disord 2006; 21: 1257-61
21. Rochester L, Jones D, Hetherington V, et al. Gait and gait-related activities and fatigue in Parkinson's disease: what is the relationship? Disabil Rehabil 2006; 28: 1365-71
22. Zenzola A, Masi G, De Mari M, et al. Fatigue in Parkinson's disease. Neurol Sci 2003; 24: 225-6
23. Friedman J, Friedman H. Fatigue in Parkinson's disease. Neurology 1993 Oct; 43: 2016-8
24. Hunt SM, McKenna SP, McEwen J, et al. The Nottingham Health Profile: subjective health status and medical consultations. Soc Sci Med 1981 May; 15A: 221-9
25. Shulman LM, Taback RL, Bean J, et al. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 2001 May; 16 (3): 507-10
26. Friedman JH, Friedman H. Fatigue in Parkinson's disease: a nine-year follow-up. Mov Disord 2001; 16: 1120-2
27. Alves G, Wentzel-Larsen T, Larsen JP. Is fatigue an independent and persistent symptom in patients with Parkinson's disease? Neurology 2004; 63: 1908-11
28. Garber CE, Friedman JH. Effects of fatigue on physical activity and function in patients with Parkinson's disease. Neurology 2003 Apr; 60: 1119-24
29. Herlofson K, Larsen JP. The influence of fatigue on healthrelated quality of life in patients with Parkinson's disease. Acta Neurol Scand 2003 Jan; 107 (1): 1-6
30. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007 Jan; 22 (1): 41-7
31. Vollestad NK. Measurement of human muscle fatigue. J Neurosci Methods 1997; 74: 219-27
32. Lou JS, Kearns G, Benice T, et al. Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled crossover study. Mov Disord 2003 Oct; 18 (10): 1108-14
33. Lou JS. Approaching fatigue in neuromuscular diseases. Phys Med Rehabil Clin N Am 2005 Nov; 16: 1063-79
34. Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of the human motor cortex. Lancet 1985 May; 1: 1106-7
35. Rothwell JC, Hallett M, Berardelli A, et al. Magnetic stimulation: motor evoked potentials. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurol Suppl 1999; 52: 97-103
36. Brasil-Neto JP, Cohen LG, Hallett M. Central fatigue as revealed by post-exercise decrement of motor evoked potentials. Muscle Nerve 1994 Jul; 17: 713-9
37. Taylor AE, Saint-Cyr JA, Lang AE, et al. Parkinson's disease and depression: a critical reevaluation. Brain 1989 Apr; 109 (Pt 2): 279-92
38. Lou JS, Benice T, Kearns G, et al. Levodopa normalizes exercise related cortico-motoneuron excitability abnormalities in Parkinson's disease. Clin Neurophysiol 2003 May; 114 (5): 930-7
39. Lou JS, Dimitrova DM, Johnson SC, et al. Modafinil reduces fatigue in PD: a double-blind, placebo-controlled pilot study [abstract]. Ann Neurol 2007; 62 (S11): S8
40. Adler CH, Caviness JN, Hentz JG, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003; 18: 287-93
41. Ondo WG, Fayle R, Atassi F, et al. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005; 76: 1636-9
42. Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc 2000; 75: 711-21
43. Oken BS, Salinsky MC, Elsas SM. Vigilance, alertness, or sustained attention: physiological basis and measurement. Clin Neurophys 2006; 117 (9): 1885-901
44. Posner MI, Petersen SE. The attention system of the human brain. Annu Rev Neurosci 1990 Dec; 13: 25-42
45. Marrocco RT, Davidson MC. Neurochemistry of attention. In: Parasuraman R, editor. The attentive brain. Cambridge (MA): MIT, 1998: 35-50
46. Corbetta M, Shulman GL. Control of goal-directed and stimulus-driven attention in the brain. Nat Rev Neurosci 2002 Mar; 3 (3): 201-15
47. Benes FM. Emerging principles of altered neural circuitry in schizophrenia. Brain Res Brain Res Rev 2000 Mar; 31 (2-3): 251-69
48. Fan J, McCandliss BD, Sommer T, et al. Testing the efficiency and independence of attentional networks. J Cogn Neurosci 2002 Apr; 14 (3): 340-7
49. Mezzacappa E. Alerting, orienting, and executive attention: developmental and socio-demographic properties in an epidemiological sample of young, urban children. Child Devel 2004 Sep - Oct; 75 (5): 1373-86
50. Rueda R, Fan J, McCandliss BD, et al. Development of attentional networks in childhood. Neuropsychologia 2004; 42 (8): 1029-40
51. Bish JP, Ferrante SM, McDonald-McGinn D, et al. Maladaptive conflict monitoring as evidence for executive dysfunction in children with chromosome 22q11.2 deletion syndrome. Dev Sci 2005 Jan; 8 (1): 36-43
52. Sobin C, Kiley-Brabeck K, Daniels S, et al. Networks of attention in children with the 22q11 deletion syndrome. Dev Neuropsychol 2004; 26 (2): 611-26
53. Wang K, Fan J, Dong Y, et al. Selective impairment of attentional networks of orienting and executive control in schizophrenia. Schizophr Res 2005 Oct; 78 (2-3): 235-41
54. Mann DM, Yates PO. Pathological basis for neuro- transmitter changes in Parkinson's disease. Neuropathol Appl Neurobiol 1983; 9 (1): 3-19
55. Gasper P, Gray F. Dementia in idiopathic Parkinson's disease: a neuropathological study of 32 cases. Acta Neuropathol 1984; 64 (1): 43-52
56. Lou JS, Dimitrova DM, Arnold GC, et al., Exacerbated objective mental fatigue in PD [abstract no. 950438]. International Congress of Movement Disorder Society; 2008 Jun 22-26; Chicago (IL)
57. Breetvelt IS, Van Dam FS. Underreporting by cancer patients: the case of response-shift. Soc Sci Med 1991; 32 (9): 981-7
58. Sprangers MA. Response-shift bias: a challenge to the assessment of patient's quality of life in cancer clinical trials. Cancer Treat Rev 1996; 22 Suppl. A: 55-62
59. Lou JS. Fatigue in amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am 2008; 19 (3): 533-43